Spooling Along: Ariad, Merck Get SPA For Phase III Trial Of Oral Deforolimus
This article was originally published in The Pink Sheet Daily
Executive Summary
Ariad seeking indication in metastatic soft tissue and bone sarcomas, with progression-free survival primary endpoint.